GLP-1 & Weight Management

Research peptides for metabolic and weight management studies including GLP-1 receptor agonists, dual and triple agonists, and metabolic modulators.

View as Grid List

Sort by

Display per page

AOD9604 6mg

Synthetic hGH Fragment: 16-amino acid C-terminal peptide (177-191), ≥98% purity
Beta-3-AR Upregulation: Enhances lipolysis while suppressing lipogenesis without IGF-1 elevation
Metabolic Research: Six human trials (900+ participants), FDA GRAS status

$48.00

NNMT Inhibitor: Small-molecule inhibitor of nicotinamide N-methyltransferase (IC50 = 1.2 μM), ≥98% purity
NAD+ Salvage Enhancement: Preserves nicotinamide for NAD+ biosynthesis; elevates intracellular NAD+ by 1.2-1.6-fold
Metabolic Research: Studied in obesity, muscle aging, cardiovascular function, and neurodegenerative disease models

$99.00

Mitochondrial Uncoupler: Selective protonophore (C₁₆H₁₀F₂N₆O), ≥98% purity
AMPK Activation: 1,000-fold greater potency than metformin per unit concentration
Metabolic Research: 50+ publications since 2014, validated in Nature Communications

$99.00

Pan-ERR Agonist Exercise Mimetic: Hydrazone small molecule (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, Saint Louis University design, activates ERRalpha/beta/gamma (EC50 98/230/430 nM), 10+ publications, all preclinical
Multi-System Metabolic Reprogramming: 70% increased endurance, 12% body weight loss, mitochondrial biogenesis via PGC-1alpha/AMPK/TFAM cascade, type IIa muscle fiber conversion, 25% increased fatty acid oxidation, reverses age-related kidney dysfunction
Clinical Status: No human trials (as of Feb 2026), all data from mouse models, well-tolerated in 8-week studies, successor compound SLU-PP-915 with improved oral bioavailability developed 2026

$89.00